51,659
Views
17
CrossRef citations to date
0
Altmetric
Review Article

ALS Untangled No. 20: The Deanna Protocol

Pages 319-323 | Published online: 02 May 2013

References

  • http://www.cbn.com/cbnnews/healthscience/2012/November/Deanna-Protocol-a-Breakthrough-for-Lou-Gehrigs/.
  • Berg JM, Tymoczko JL, Stryer L. In: Freeman WH, editor. Biochemistry: 5th edn. New York: 2002.
  • Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329: 2002–12.
  • Liu Y, Lange R, Langansky J, Hamma T, Yang B, Steinacker JM. Improved training tolerance by supplementation with alpha-keto acids in untrained young adults: a randomized, double-blind, placebo-controlled trial. J Int Soc Sports Nutr. 2012;9:37.
  • Hammarqvist F, Wernerman J, von der Decken A, Vinnars E.Alpha-ketoglutarate preserves protein synthesis and free glutamine in skeletal muscle after surgery. Surgery. 1991;109:28–36.
  • Joyner MJ. Glutamine and arginine: immunonutrients and metabolic modulators?Exerc Sport Sci Rev. 2005;33: 105–6.
  • Carbone C, Pignatello R, Musumeci T, Puglisi G. Chemical and technological delivery systems for idebenone: a review of literature production. Expert Opin Drug Deliv. 2012;9: 1377–92.
  • Foerster BR, Callaghan BC, Petrou M, Edden RAE, Chenevert TL, Feldman EL. Decreased motor cortex gamma-aminobutyric acid in amyotrophic lateral sclerosis. Neurology. 2012;78:1596–600.
  • D’Alessandro G, Calcagno E, Tartari S, Rizzardini M, Invernizzi R, Cantoni L. Glutamate and glutathione interplay in a motor neuronal model of amyotrophic lateral sclerosis reveals altered energy metabolism. Neurobiol Dis. 2011;43:346–55.
  • Martin LJ. Mitochondrial pathobiology in ALS. J Bioenerg Biomembr. 2011;43:569–79.
  • Swerdlow RH, Parks J, Cassarino D, Trimmer P, Miller S, Maguire D, et al. Mitochondria in sporadic amyotrophic lateral sclerosis. Exp Neurol. 1998;153:135–42.
  • Tieu K, Perier C, Caspersen C, Teismann P, Wu DC, Yan SD, et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson’s disease. J Clin Invest. 2003;112:892–901.
  • Redler RL, Dokholyan NV.The complex molecular biology of amyotrophic lateral sclerosis (ALS). Prog Mol Biol Transl Sci. 2012;107:215–62.
  • Cleveland DW, Rothstein J. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001;2:806–19.
  • Lacomblez L, Bensimon G, Leigh PN, Guillet P, Powe L, Durrleman S, et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology. 1996;47(Suppl 4):S242–50.
  • Petri S, Korner S, Kiaei M. Nrf2/ARE Signaling Pathway: Key Mediator in Oxidative Stress and Potential Therapeutic Target in ALS. Neurol Res Int. 2012;2012:878030.
  • Borg J, London J.Copper/zinc superoxide dismutase overexpression promotes survival of cortical neurons exposed to neurotoxins in vitro. J Neurosci Res. 2002;70:180–9.
  • Personal communication with Dominic D’Agostino, Department of Molecular Pharmacology and Physiology at the University of Southern Florida.
  • Zhao Z, Lange D, Voustianiouk A, MacGrogan D, Ho L, Suh J, et al. A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci. 2006;7:29.
  • Matthews RT, Yang L, Browne S, Bajk M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998;95:8892–7.
  • Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine. 1999;5:347–50.
  • Kaufmann P, Thompson JL, Levy G, Buschsbaum R, Shefner J, Krivickas L, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66:235–44.
  • Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews. 2012;12:1–27.
  • Ghoddoussi F, Galloway MP, Jambekar A, Bame M, Needleman R, Brusilow WS. Methionine sulfoximine, an inhibitor of glutamine synthetase, lowers brain glutamine and glutamate in a mouse model of ALS. J Neurol Sci. 2010; 290:41–7.
  • Ghadge GD, Slusher B, Bodner A, Dal Canto M, Wozniak K, Thomas A, et al. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci U S A. 2003;100:9554–9.
  • Wang R, Zhang D. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci. 2005;22:2376–80.
  • Rothstein JD, Sarjubhai P, Melissa R, Haenggeli C, Huang Y, Bergles D, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433:73–7.
  • Verstraete E, Veldink J, Huisman M, Draak T, Uijtendaal E, van der Kooi A, et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomized sequential trial. J Neurol Neurosurg Psychiatry. 2012;83:557–64.
  • http://www.alsworldwide.org/ceftriaxone.html.
  • de Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A.A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:456–60.
  • Ryberg H, Askmark H, Persson L. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol Scand. 2003;108:1–8.
  • Miller RG, Moore DH, Gelinas D, Dronsky V, Mendoza M, Barohn R, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 2001;56:843–8.
  • Krochmal R, Hardy M, Bowerman S, Lu Q, Wang H, Elashoff R, Heber D. Phytochemical assays of commercial botanical dietary supplements, eCAM. 2004;1:305–13.
  • http://www.iom.edu/Activities/Nutrition/SummaryDRIs/˜/media/Files/Activity%20Files/Nutrition/DRIs/5_Summary%20Table%20Tables%201-4.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.